Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Feb;48(2):539-44.
doi: 10.1128/JCM.01505-09. Epub 2009 Dec 9.

Correlation of genotype and in vitro susceptibilities of Cryptococcus gattii strains from the Pacific Northwest of the United States

Naureen Iqbal  1 , Emilio E DeBess, Ron Wohrle, Ben Sun, Randall J Nett, Angela M Ahlquist, Tom Chiller, Shawn R Lockhart; Cryptococcus gattii Public Health Working Group
Affiliations

Correlation of genotype and in vitro susceptibilities of Cryptococcus gattii strains from the Pacific Northwest of the United States

Naureen Iqbal et al. J Clin Microbiol. 2010 Feb.

Abstract

Cryptococcus gattii emerged in North America in 1999 as a human and veterinary pathogen on Vancouver Island, British Columbia. The emergent subtype, VGIIa, and the closely related subtype VGIIb can now be found in the United States in Washington, Oregon, and California. We performed multilocus sequence typing and antifungal susceptibility testing on 43 isolates of C. gattii from human patients in Oregon, Washington, California, and Idaho. In contrast to Vancouver Island, VGIIa was the most frequent but not the predominant subtype in the northwest United States. Antifungal susceptibility testing showed statistically significant differences in MICs between the subtypes. This is the first study to apply antifungal susceptibility testing to C. gattii isolates from the Pacific Northwest and the first to make direct comparisons between subtypes.

PubMed Disclaimer

References

    1. Aller, A. I., E. Martin-Mazuelos, F. Lozano, J. Gomez-Mateos, L. Steele-Moore, W. J. Holloway, M. J. Gutiérrez, F. J. Recio, and A. Espinel-Ingroff. 2000. Correlation of fluconazole MICs with clinical outcome in cryptococcal infection. Antimicrob. Agents Chemother. 44:1544-1548. - PMC - PubMed
    1. Bovers, M., F. Hagen, and T. Boekhout. 2008. Diversity of the Cryptococcus neoformans-Cryptococcus gattii species complex. Rev. Iberoam. Micol. 25:S4-S12. - PubMed
    1. Brandt, M. E., L. C. Hutwagner, L. A. Klug, W. S. Baughman, D. Rimland, E. A. Graviss, R. J. Hamill, C. Thomas, P. G. Pappas, A. L. Reingold, and R. W. Pinner. 1996. Molecular subtype distribution of Cryptococcus neoformans in four areas of the United States. Cryptococcal Disease Active Surveillance Group. J. Clin. Microbiol. 34:912-917. - PMC - PubMed
    1. Byrnes, E. J., III, R. J. Bildfell, S. A. Frank, T. G. Mitchell, K. A. Marr, and J. Heitman. 2009. Molecular evidence that the range of the Vancouver Island outbreak of Cryptococcus gattii infection has expanded into the Pacific Northwest in the United States. J. Infect. Dis. 199:1081-1086. - PMC - PubMed
    1. Chen, S., T. Sorrell, G. Nimmo, B. Speed, B. Currie, D. Ellis, D. Marriott, T. Pfeiffer, D. Parr, and K. Byth. 2000. Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Australasian Cryptococcal Study Group. Clin. Infect. Dis. 31:499-508. - PubMed

LinkOut - more resources